Natera

NTRA · NASDAQ

$405.92+$6.50 (+1.63%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $399.42

Latest news

Press releaseOct 18, 6:10 PM ETBusiness Wire
ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
Press releaseOct 15, 12:46 PM ETBusiness Wire
Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
Press releaseOct 13, 7:30 AM ETBusiness Wire
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
NewsOct 12, 6:10 AM ET
Natera Reports Q2 2026 Results: Full Earnings Call Transcript
Press releaseOct 9, 8:00 AM ETBusiness Wire
FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
Press releaseOct 7, 8:00 AM ETBusiness Wire
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
Press releaseOct 6, 8:00 AM ETBusiness Wire
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Press releaseOct 5, 8:00 AM ETBusiness Wire
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NewsSep 29, 4:32 PM ETChris Katje
Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You
NewsSep 28, 7:38 AM ETAvi Kapoor
Natera, UnitedHealth Group And A Tech Stock On CNBC’s ‘Final Trades’
NewsSep 22, 8:24 AM ETAvi Kapoor
Uber, Micron, Datadog And A Health Care Stock: CNBC’s ‘Final Trades’
NewsSep 22, 8:06 AM ET
Japan’s Pharmaceuticals And Medical Devices Agency Issues Regulatory Approval To Natera's Signatera Test
Press releaseSep 22, 8:00 AM ETBusiness Wire
Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Press releaseSep 18, 6:00 AM ETBusiness Wire
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
Press releaseSep 1, 6:00 AM ETBusiness Wire
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
Press releaseAug 28, 11:03 AM ETBusiness Wire
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
Press releaseAug 27, 6:00 AM ETBusiness Wire
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
Press releaseAug 12, 6:00 AM ETBusiness Wire
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
NewsAug 7, 2:35 PM ETVandana Singh
Natera CEO Says Company Is 'Clearly on a Roll' After Record Test Volumes, Raises Outlook
NewsAug 7, 8:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsAug 6, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseAug 6, 4:05 PM ETBusiness Wire
Natera Reports Second Quarter 2026 Financial Results
Press releaseAug 5, 6:00 AM ETBusiness Wire
Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Press releaseJul 30, 8:00 AM ETBusiness Wire
Natera to Report its Second Quarter Results on August 6, 2026
Press releaseJul 22, 6:00 AM ETBusiness Wire
Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
NewsJul 21, 2:52 PM ETVandana Singh
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
Press releaseJul 16, 6:35 PM ETBusiness Wire
Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
Press releaseJul 9, 6:00 AM ETBusiness Wire
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
Press releaseJul 6, 6:00 AM ETBusiness Wire
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
Press releaseJun 29, 6:00 AM ETBusiness Wire
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
NewsJun 25, 7:08 AM ET
Natera Partners With Eledon Pharmaceuticals To Incorporate Its Prospera Kidney Transplant Assessment Test Into Eledon’s Planned Phase 3 Clinical Trial Of Tegoprubart, An Investigational Therapy Designed To Prevent Organ Rejection In Kidney Transplantation
Press releaseJun 25, 7:00 AM ETBusiness Wire
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
NewsJun 24, 2:14 PM ETVandana Singh
Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer
Press releaseJun 24, 3:00 AM ETBusiness Wire
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
NewsJun 23, 12:59 PM ETVandana Singh
Why Is Natera Stock Gaining Tuesday?
Press releaseApr 30, 8:00 AM ETBusiness Wire
Natera to Report its First Quarter Results on May 7, 2026
NewsApr 9, 8:19 AM ETNabaparna Bhattacharya
Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle
NewsFeb 27, 8:01 AM ET
Forecasting The Future: 10 Analyst Projections For Natera

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Natera Reports Q2 2026 Results: Full Earnings Call Transcript

FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay

Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma

New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists

Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You

Natera, UnitedHealth Group And A Tech Stock On CNBC’s ‘Final Trades’

Uber, Micron, Datadog And A Health Care Stock: CNBC’s ‘Final Trades’

Japan’s Pharmaceuticals And Medical Devices Agency Issues Regulatory Approval To Natera's Signatera Test

Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM

New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Natera CEO Says Company Is 'Clearly on a Roll' After Record Test Volumes, Raises Outlook

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's After-Market Session

Natera Reports Second Quarter 2026 Financial Results

Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

Natera to Report its Second Quarter Results on August 6, 2026

Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study

Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring

Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio

Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers

Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer

Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer

Natera Partners With Eledon Pharmaceuticals To Incorporate Its Prospera Kidney Transplant Assessment Test Into Eledon’s Planned Phase 3 Clinical Trial Of Tegoprubart, An Investigational Therapy Designed To Prevent Organ Rejection In Kidney Transplantation

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer

Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer

Why Is Natera Stock Gaining Tuesday?

Natera to Report its First Quarter Results on May 7, 2026

Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle

Forecasting The Future: 10 Analyst Projections For Natera